December 07, 2011 -- CalAsia and LD Biopharma have agreed to provide integrated discovery services for structure-based and fragment-based drug discovery.
CalAsia and LD Biopharma (both at San Diego, USA) have entered into an agreement to provide integrated discovery services for structure-based and fragment-based drug discovery to interested life-science customers. The integration of these complementary capabilities leads to a unique and unprecedented offering of discovery services using E.coli derived inclusion body temperature_ shift / matrix buffer refolding technology, functional screening of fragments, co-crystallization, soak-in and soak-out technology, differential fragment screening, along with protein X-ray crystallography and medicinal chemistry.
CalAsia: http://www.calasiapharma.com/
LD Biopharma Inc: http:// ldbiopharma.com
